A Drug Designed to Treat PTSD?
Esquire, July 9, 2012

“If we were to invent a drug designed to treat PTSD, what qualities would it have?” asks MDMA researcher Ben Sessa, M.D. Neil Boorman of Esquire magazine describes his experience taking part in the UK’s first study of the effects of MDMA on the brain.

MDMA On Trial in the UK
The Guardian, July 19, 2012

Professor David Nutt of Imperial College London writes for the Guardian about his current MDMA research project. With funding from Channel 4, a U.K. television station, and help from Professor Val Curran of University College London, Nutt has been able to measure resting brain activity in healthy volunteers after receiving a pure dose of MDMA. Channel 4 will air footage of the research along with a live debate about MDMA in two 60-minute installments of a special program titled Drugs Live: The Ecstasy Trial.

MDMA Turns 100 Years Old, Still Faces Stereotypes
Care2, June 27, 2012

Care2 delves into the history of MDMA and its place in science and medicine. Brad Burge, MAPS’ Director of Communications, is interviewed and details MAPS’ research focusing on MDMA-assisted psychotherapy as a treatment for PTSD and also talks about the future of MDMA as a therapeutic drug.

Shaping the Renaissance of Psychedelic Research
The Lancet, July 21, 2012

Ben Sessa writes for The Lancet about the current state of psychedelic research.

Are We Finally Reawakening to the Profound Healing Properties of Psychedelics?
AlterNet, June 14, 2012

AlterNet covers the wide variety of uses for psychedelics and marijuana, highlighting the various histories and medical potential of the drugs. The article features a transcript of the talks given at Reform Conference by MAPS Founder Rick Doblin, Ph.D., and Executive Director of The Beckley Foundation Executive Director, Amanda Feilding.

Doors Reopen for LSD
Época, June 18, 2012

Época summarizes the vast history of LSD. In the 1960s, researchers studied the effects of LSD and its potential as a treatment for schizophrenia and depression. Despite its widespread prohibition, research on LSD has begun to take place once again with studies across the world looking into LSD-assisted therapy for end-of-life anxiety and depression.
MAPS Shares in $10 Million Bequest

Chronicle of Philanthropy, June 24, 2012

The Chronicle of Philanthropy details the $5 million bequest given to MAPS from software pioneer Ashawna Hailey. The bequest will go primarily towards research on using MDMA-assisted therapy to treat PTSD. Hailey was a board member of MAPS and cared deeply about drug policy reform. She also left $1.25-million each to the American Civil Liberties Union, Drug Policy Alliance, Marijuana Policy Project, and Second Harvest Food Bank.

California Pot Research Backs Therapeutic Claims

Sacramento Bee, July 12, 2012

The Sacramento Bee examines the recent completion of medical marijuana research conducted in California by the Center for Medical Cannabis Research (CMCR). The studies lasted over a decade and treated more than 300 patients, concluding that marijuana can offer benefits for treating pain from injuries, HIV, strokes, and other conditions. The article also highlights MAPS’ medical marijuana research plans.

Analyzing the Role of Cannabidiol in Medicinal Cannabis

HerbalGram, July 9, 2012

The official journal of the American Botanical Council sorts out the science behind the medical uses of cannabidiol (CBD, an active component of marijuana similar to THC and with different effects) and describes researchers’ efforts to understand the real risks and benefits of all components of the cannabis plant.

Donald Abrams, M.D., presents the results of his groundbreaking research on medical marijuana at MAPS’ 25th Anniversary Conference. Dr. Abrams is Chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California, San Francisco.

Read the full articles at www.maps.org/media